Sofinnova Partners Congratulates Portfolio Company DNA Script for the Success of Its €142M ($165M) Oversubscribed Series C Fundraise
26.10.2021 16:00:00 EEST | Business Wire | Press release
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its portfolio company DNA Script has raised €142 million ($165 million) in a Series C financing led by top global investors, bringing the total amount raised to date by the company to €236 million ($280 million). DNA Script is a pioneer in Enzymatic DNA Synthesis (EDS) and DNA printing on demand. The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform and broaden the portfolio of products powered by EDS.
DNA Script is a leader in enzymatic DNA synthesis and has developed a revolutionary platform that provides in-house DNA printing using a sustainable process that eliminates the use of toxic organic chemicals. The company’s ground-breaking approach to DNA printing significantly shortens wait times by enabling labs of all sizes to take full control of their DNA printing needs from the comfort of their own facilities – like having a home printer. No longer having to rely on third-party providers, researchers gain unprecedented control and autonomy, ultimately helping to accelerate innovation.
Joško Bobanović, Partner at Sofinnova Partners, said: “As the first institutional investor in DNA Script, it is incredibly gratifying to have been part of the growth and evolution of the company from the start. This milestone confirms our early conviction in the strength of the team and the magnitude of their vision to revolutionize a well-established chemical technology by applying biotechnology. The overwhelming interest from the global community further affirms our long-standing belief in the uniqueness and potential of the company’s technology to fundamentally change how DNA is synthesized by mimicking nature, while remaining entirely sustainable.”
Thomas Ybert, co-founder and CEO of DNA Script, said: “Sofinnova Partners was our first institutional investor and a strong believer in our vision from the beginning. Their hands-on role throughout critical early-stage financing rounds, and as an active member of our Board of Directors, has been instrumental in enabling us to rapidly scale to become a global operation and attract top notch investors from all over the world.”
The Sofinnova Industrial Biotech strategy is part of Sofinnova’s multi-fund investment platform that covers the entire life sciences value chain. It is a highly-targeted strategy that seeks to invest in start-ups that are addressing global sustainability issues in food, agricultural, chemicals and materials markets.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
About DNA Script
Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005360/en/
Contact information
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Rafaella Casula
rafaella.casula@havaspr.com
+39 (0) 345 3780834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Heaviside Industries Unveils the TYR Loitering Munition, A Five-Pound Tank-Killer12.10.2026 13:00:00 EEST | Press release
Heaviside Industries, a builder of multi-domain precision munitions platforms, today introduced its TYR miniaturized loitering munition at the AUSA Annual Meeting & Exposition in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012159239/en/ The first in Heaviside’s line of precision munitions, TYR delivers outsized performance for its weight, combining speed, endurance, and lethal effects in a truly man-packable system. Weighing just over five pounds with a total system weight of approximately 15 pounds, TYR can defeat a wide range of targets, including main battle tanks. TYR offers four Nammo warhead variants — Shaped Charge Anti-Tank, Anti-Structure Munition, Explosively Formed Penetrator, and Anti-Personnel Frag — allowing warfighters to tailor lethal effects across multiple mission sets. TYR can be employed in ground and base defense operations, utilized as a counter-UAS system, or integrated onto larg
Navan Selected by Investec to Modernize Global Travel Program12.10.2026 11:00:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Investec, a leading international bank and wealth manager, to upgrade its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009977645/en/ Leading international bank and wealth manager chooses Navan to deliver an AI-first travel program “As Investec continues its digital transformation, we’re excited to partner with an AI-first travel platform to increase adoption and improve operational efficiency,” said Lyndon Subroyen, Investec Group Chief Technology and Operating Officer. As a dual-listed company in the United Kingdom and South Africa, Investec sought a partner to consolidate its travel operations, reduce administrative work, and improve the booking experience for its workforce. Investec needed a solution to increase platform adoption and help employees travel more cost-efficient
Opensignal Launches World’s First Interactive Map of Satellite-to-Smartphone D2D Connections12.10.2026 11:00:00 EEST | Press release
Opensignal, a global independent consumer connectivity analytics and insights company, today launched the Opensignal D2D Satellite Map, the world’s first interactive, real-world depiction of where direct-to-device (D2D) satellite connections with smartphones are happening across the globe. Every point on the map, which will be updated monthly, represents a location where smartphones have connected to a D2D service since January 2026, extracted from Opensignal’s billions of real-world measurements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261011884935/en/ Opensignal D2D Satellite Map “D2D is reshaping who can deliver mobile coverage, and where, because the phone in your pocket can now reach a satellite directly. Until now, the industry has had to make decisions without knowing where momentum and adoption are real,” said Mike Sandy, President, Market Performance at Opensignal. “The Opensignal D2D Satellite Map provides a
Demand for Tech Services in Europe Continues to Surge, Led by AI-Driven Infrastructure Spending in Q3: ISG Index™12.10.2026 11:00:00 EEST | Press release
Surging AI demand propelled Europe’s technology services market to a new high in the third quarter, as infrastructure spending more than doubled and traditional managed services grew by double digits, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, finds. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both managed services and cloud-based infrastructure and software services) soared 56 percent—its fastest growth in eight years—to US $14.9 billion. It was the fourth straight quarter that combined ACV growth has exceeded 20 percent, averaging 39 percent in that span. “The European market is absolutely roaring right now,” said Anthony Drake, president, ISG EMEA. “After surpassing US $10 billion for the first time in last year’s fourth quarter, demand continu
Carta Secures Authorization to Operate as Fund Administrator and Transfer Agent in Luxembourg12.10.2026 11:00:00 EEST | Press release
Carta, the connected platform and AI-native ecosystem for private capital, today announced it has received authorization to operate as a fully-licensed Specialised Professional of the Financial Sector (PSF) under the supervision of the CSSF (Commission de Surveillance du Secteur Financier) in Luxembourg. The authorization covers five statutory functions — registrar agent, corporate domiciliation agent, company incorporation and management services, administrative agent of the financial sector, and client communication agent — adding licensed fund administration and transfer agency directly to a platform already serving Luxembourg fund managers. Luxembourg is the second-largest fund domicile in the world, home to approximately 5,000 alternative investment fund entities managing over €1 trillion in assets. It is also the preferred jurisdiction for over 1,000 US and APAC fund managers running parallel or feeder structures, representing more than $333 billion in AUM. For managers operating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom